We only have this paper's title and publication details.
Read it at the sourcecells, highlighting PARP1 and USP3 as possible therapeutic targets in neurological disease.
No takes yet. Share an insight, caveat, or question.
Adamowicz et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: